Inflammasome and IL-1β-mediated disorders

Current Allergy and Asthma Reports

Volumn 10, Issue 4, 2010, Pages 229-235

  Hoffman, Hal M ^a   Wanderer, Alan A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Colorado Health Sciences Center   (United States)

Author keywords

Autoinflammatory; Biologic therapy; Cryopyrin; Inflammasome; Interleukin 1; Neutrophil; NLRP3

Indexed keywords

BLEOMYCIN; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; ETANERCEPT; INFLAMMASOME; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ADULT ONSET STILL DISEASE; ASBESTOSIS; BRAIN ISCHEMIA; CINCA SYNDROME; CONTACT ALLERGY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; FAMILIAL MEDITERRANEAN FEVER; GOUT; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFLAMMATORY DISEASE; INJECTION SITE PAIN; JUVENILE RHEUMATOID ARTHRITIS; LUNG DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAPA SYNDROME; PROTEIN TARGETING; RADIATION INJURY; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SCHNITZLER SYNDROME; SEPSIS; SICKLE CELL ANEMIA; SILICOSIS; SKIN DEFECT; SOLID TUMOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ANIMAL; DRUG ANTAGONISM; IMMUNOLOGY; INFLAMMATION; MOUSE;

ANIMALS; ASBESTOSIS; CARRIER PROTEINS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DIABETES MELLITUS, TYPE 2; GOUT; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; LUNG DISEASES; MICE; SILICOSIS;

EID: 77956394358     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-010-0109-z     Document Type: Review

References (33)

1. Martinon F, Burns K, Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
2. Martinon F, Mayor A, Tschopp J: The inflammasomes: Guardians of the body. Annu Rev Immunol 2009, 27:229-265. This is an excellent review of inflammasome function.
3. Hoffman HM, Mueller JL, Broide DH, et al.: Mutation of a new gene encoding a putative pyrin-like protein cause familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305.
4. Mertens M, Singh JA: Anakinra for rheumatoid arthritis: A systematic review. J Rheumatol 2009, 36:1118-1125.
5. Hoffman HM: Rilonacept for the treatment of cryopyrinassociated periodic syndromes (CAPS). Expert Opin Biol Ther 2009, 9:519-531.
6. Savic S, McDermott MF: Inflammation: Canakinumab for the cryopyrin-associated periodic syndromes. Nat Rev Rheumatol 2009, 5:529-530.
7. Hoffman HM, Throne ML, Amar NJ, et al.: Efficacy and safety of rilonacept (interleukin-1 TRAP) in patients with cryopyrinassociated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452.
8. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
9. Terkeltaub R, Sundy JS, Schumacher HR, et al.: The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
10. Aksentijevich I, Putnam CD, Remmers EF, et al.: The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273-1285.
11. Hoffman HM, Rosengren S, Boyle DL, et al.: Prevention of coldassociated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
12. So A: Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10:221.
13. Zhou R, Tardivel A, Thorens B, et al.: Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010, 11:136-140.
14. Maedler K, Dharmadhikari G, Schumann DM, Størling J: Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 2009, 9:1177-1188.
15. Gasse P, Riteau N, Charron S, et al.: Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009, 179:903-913.
16. Piguet PF, Vesin C, Grau GE, Thompson RC: Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993, 5:57-61.
17. Dostert C, Petrilli V, Van Bruggen R, et al.: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
18. Watanabe H, Gaide O, Petrilli V, et al.: Activation of the IL-1 [beta]-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007, 127:1956-1963.
19. Masters SL, Simon A, Aksentijevich I, Kastner DL: Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009, 27:621-668. This is a comprehensive review of autoinflammatory syndromes.
20. Belkhir R, Moulonguet-Doleris L, Hachulla E, et al.: Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007, 146:825-826.
21. Hull KM, Aksentijevich I, Singh HK: Efficacy of etanercept for the treatment of patients with TNF receptor-associated periodic syndrome (TRAPS) [abstract]. Arthritis Rheum 2003, 46:S378.
22. Simon A, Bodar EJ, van der Hilst JC, et al.: Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004, 117:208-210.
23. Drewe E, Powell RJ, McDermott EM: Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology 2007, 46:1865-1866.
24. Cailliez M, Garaix F, Rousset-Rouviére C, et al.: Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndromeassociated febrile crisis. J Inherit Metab Dis 2006, 29:763.
25. Brenner M, Ruzicka T, Plewig G, et al.: Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009, 161:1199-1201.
26. Aksentijevich I, Masters SL, Ferguson PJ, et al.: An autoinflammatory disease with deficiency of the interleukin-1- receptor antagonist. N Engl J Med 2009, 360:2426-2437.
27. Lequerre T, Quartier P, Rosellini D, et al.: Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in France. Ann Rheum Dis 2008, 67:302-308.
28. Zeft AMD, Hollister RMD, LaFleur BP, et al.: Anakinra for systemic juvenile arthritis: The Rocky Mountain experience. J Clin Rheumatol 2009, 15:161-164.
29. de Koning HD, Bodar EJ, Simon A, et al.: Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis 2006, 65:54-544.
30. Faustin B, Reed JC: Sunburned skin activates inflammasomes. Trends Cell Biol 2008, 18:4-8.
31. Wanderer AA: Corticosteroid resistance in pulmonary neutrophilic inflammatory disorders and rationale for adjunct IL-1{beta} targeted therapy. Am J Respir Cell Mol Biol 2009, 41:246-247.
32. Wanderer AA: Rationale for IL-1[beta] targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease. J Pediatr Hematol Oncol 2009, 31:537-538.
33. Wanderer AA: Rationale for IL-1[beta]-targeted therapy to minimize hypoxic-ischemic encephalopathy. J Perinatol 2009, 29:785-787.